1 |
Brambilla G, Martelli A (1993). Human hepatocyte primary cultures in toxicity assessment. Cytotechnol, 11, 6-8.
DOI
ScienceOn
|
2 |
Kafert-Kasting S, Alexandrova K, Barthold M, et al (2006). Enzyme induction in cryopreserved human hepatocyte cultures. Toxicol, 220, 117-25.
DOI
ScienceOn
|
3 |
Kandil DH, Cooper K (2009). Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9.
DOI
ScienceOn
|
4 |
Kang S-J, Jeong S-H, Kim E-J, et al (2013). Evaluation of hepatotoxicity of chemicals using hepatic progenitor and hepatocyte-like cells derived from mouse embryonic stem cells. Cell biol and toxicol, 29, 1-11.
DOI
ScienceOn
|
5 |
Maier P (1989). Development of hepatocyte cultures in toxicity testing. Altex, 6, 38.
|
6 |
Nakatsura T, Yoshitake Y, Senju S, et al (2003). Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Bioph Res Commun, 306, 16-25.
DOI
ScienceOn
|
7 |
Nussler A, Wang A, Neuhaus P, et al (2001). The suitability of hepatocyte culture models to study various aspects of drug metabolism. Altex, 18, 91.
|
8 |
Okura H, Komoda H, Saga A, et al (2009). Properties of hepatocyte-like cell clusters from human adipose tissue-derived mesenchymal stem cells. Tissue Eng Part C Methods, 16, 761-70.
|
9 |
Rambhatla L, Chiu C-P, Kundu P, et al (2003). Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant, 12, 1-11.
DOI
ScienceOn
|
10 |
Ratanasavanh D, Baffet G, Latinier M, et al (1988). Use of hepatocyte co-cultures in the assessment of drug toxicity from chronic exposure. Xenobiotica, 18, 765-71.
DOI
|
11 |
Visvader JE, Lindeman GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews. Cancer, 8, 755-68.
|
12 |
Yao M, Yao DF, Bian YZ, et al (2011). Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. HBPD INT, 10, 289-94.
|
13 |
Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89.
DOI
ScienceOn
|
14 |
Fausto N, Campbell JS (2010). Mouse models of hepatocellular carcinoma. In Seminars in liver disease, 30, 87-98.
|
15 |
Filmus J, Church J, Buick R (1988). Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol, 8, 4243-9.
DOI
|
16 |
Gomez-Lechon MJ, Castell JV, Donato MT (2010). The use of hepatocytes to investigate drug toxicity. In Hepatocytes, 640, 389-415.
DOI
ScienceOn
|
17 |
Greenhough S, Medine CN, Hay DC (2010). Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicol, 278, 250-5.
DOI
ScienceOn
|
18 |
Grozdanov PN, Yovchev MI, Dabeva MD (2006). The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest, 86, 1272-84.
DOI
ScienceOn
|
19 |
Guillouzo A, Morel F, Fardel O, Meunier B (1993). Use of human hepatocyte cultures for drug metabolism studies. Toxicology, 82, 209-19.
DOI
ScienceOn
|
20 |
Hamazaki T, Iiboshi Y, Oka M, et al (2001). Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS letters, 497, 15-9.
DOI
ScienceOn
|
21 |
Hammond AH, Garle MJ, Fry JR (1995). Mechanism of toxicity of precocene II in rat hepatocyte cultures. J Biochem Toxicol, 10, 265-73.
DOI
|
22 |
Ho DW, Yang ZF, Yi K, et al (2012). Gene expression profiling of liver cancer stem cells by RNA-sequencing. PloS one, 7, 37159.
DOI
|
23 |
Reich-Slotky R, Bonneh-Barkay D, Shaoul E, et al (1994). Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem, 269, 32279-85.
|
24 |
Sell S, Dunsford HA (1989). Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. The Am J Pathol, 134, 1347-63.
|
25 |
Shirakawa H, Kuronuma T, Nishimura Y, et al (2009a). Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol, 34, 649-56.
|
26 |
Shirakawa H, Suzuki H, Shimomura M, et al (2009b). Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 100, 1403-7.
DOI
ScienceOn
|
27 |
Song HH, Shi W, Filmus J (1997). OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem, 272, 7574-7.
DOI
ScienceOn
|
28 |
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A (2010). Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroentero, 16, 418.
DOI
ScienceOn
|
29 |
Sung YK, Hwang SY, Park MK, et al (2003). Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Science, 94, 259-62.
DOI
ScienceOn
|
30 |
Touboul T, Hannan NR, Corbineau S, et al (2010). Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51, 1754-65.
DOI
ScienceOn
|
31 |
Vesselinovitch S, Koka M, Mihailovich N, Rao K (1984). Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J Cancer Res Clin Oncol, 108, 60-5.
DOI
ScienceOn
|